home / stock / embi / embi news


EMBI News and Press, Emerald Bioscience Inc From 01/09/20

Stock Information

Company Name: Emerald Bioscience Inc
Stock Symbol: EMBI
Market: OTC

Menu

EMBI EMBI Quote EMBI Short EMBI News EMBI Articles EMBI Message Board
Get EMBI Alerts

News, Short Squeeze, Breakout and More Instantly...

EMBI - Emerald Bioscience to Present at Biotech Showcase 2020

Long Beach, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murp...

EMBI - Emerald Bioscience Announces Financing Update and Board Re-organization

Emerald Health Sciences To Exercise 40.8 Million Warrants, Reducing Outstanding Debt, As Company Changes Name to Embi Pharmaceuticals   Punit Dhillon Assumes Board Chairmanship as Dr. Avtar Dhillon Transitions to Board Observer Role LONG BEACH, CA, Dec. 23, 2019 (GLOBE...

EMBI - Emerald Bioscience Inc. Announces Cannabidiol-Valine-Hemisuccinate Possesses Enhanced Anti-Seizure Activity when Compared with Cannabidiol (CBD) in the StemoniX Human Neural Tissue Platform

Long Beach, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that data generated by Stem...

EMBI - Emerald Bioscience Reports its Proprietary Analog of Cannabidiol, Cannabidiol-Valine-Hemisuccinate (CBDVHS), Exhibits Greater Potency and Antifibrotic Activity than Cannabidiol (CBD) in Biomarker Studies in Human Ocular Donor Tissues

CBDVHS Also Displayed Superior Anti-Inflammatory Activity When Compared to CBD Indicating Potential Use in Diseases of the Retina Unlike CBD, CBDVHS was not Associated with Biomarkers Related to Elevation of Intraocular Pressure (IOP)  LONG BEACH, CA, Dec. 09, 2019 (GLOBE N...

EMBI - Emerald Bioscience Announces $2.0 Million Registered Direct Offering

Long Beach, CA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced i...

EMBI - Alibaba And Disney Step Out (Stocks To Watch Podcast)

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...

EMBI - Stocks To Watch: Alibaba And Disney Step Out

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

EMBI - Emerald Bioscience to Present at Cowen 2nd Annual Boston Cannabis Conference

LONG BEACH, CA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murphy, Chief Executive Offi...

EMBI - Emerald Bioscience to Present Research Data Related to its Glaucoma Drug Candidate, NB1111, at 2019 American Association of Pharmaceutical Scientists

Long Beach, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that the Universi...

EMBI - Emerald Bioscience's NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model

LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced data demons...

Previous 10 Next 10